Revised SPC: Tasigna (nilotinib) Hard Capsules (all strengths)

Source:
electronic Medicines Compendium - eMC
Publisher:
electronic Medicines compendium
Publication date:
09 December 2019

Abstract

Sections 4.4 and 4.8 have been updated to advise that in the paediatric population, growth retardation has been documented in patients treated with nilotinib. Close monitoring of growth in paediatric patients under nilotinib treatment is recommended.